Marit Sjo Lorentzen

Director de Operaciones en ARCTICZYMES TECHNOLOGIES ASA .

Fortuna: 49 562 $ al 31/05/2024

56 años

Health Technology

Consumer Services

Cargos activos de Marit Sjo Lorentzen

Empresas	Cargo	Inicio	Fin
ARCTICZYMES TECHNOLOGIES ASA	Director de Operaciones	-	-
ARCTICZYMES TECHNOLOGIES ASA	Director/Miembro de la Junta	-	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Director/Miembro de la Junta	-	-

University of Tromso

Undergraduate Degree

Internacional

Noruega

Operativa

Sectorial

Health Technology	3
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Empresas privadas	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology

Empresas privadas

Health Technology